Landos Biopharma, Inc.
Landos Biopharma, Inc. (LABP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
labp · stock forecast · 7 analysts (3M) · FMP · updated Aug 27, 2025
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Hold
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $22.93
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $23.02 | ↑ 0.38% |
1-day model range: $22.99–$23.05. Peak: $23.05 (+0.38%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LABP · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-04-01 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-01-06 | Jefferies | Downgrade ↓ | Hold→Underperform |
| 2022-11-11 | SVB Leerink | Maintains | Market Perform→Market Perform |
| 2022-08-12 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
| 2022-08-12 | SVB Leerink | Maintains | Market Perform→Market Perform |
| 2022-04-12 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2022-03-25 | Raymond James | Maintains | Outperform→Outperform |
| 2022-01-03 | JP Morgan | Maintains | Neutral→Neutral |
| 2021-11-16 | SVB Leerink | Downgrade ↓ | Outperform→Market Perform |
| 2021-10-20 | Craig-Hallum | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Landos Biopharma, Inc. (LABP) stock. Of the recent 17 rating actions, 0 were upgrades and 5 were downgrades. 7 analysts currently cover LABP.
Analyst Recommendation Trends
LABP analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
EPS This Year
$-2.35
EPS Next Year
$-2.07
↓ 11.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast LABP EPS of $-2.35 for the current fiscal year, based on estimates from 1 analysts. The LABP revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The LABP stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LABP price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The LABP short-term stock prediction for tomorrow is $23.02 (+0.38%).
Landos Biopharma, Inc. trades on NASDAQ under the ticker LABP. The LABP stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 29% of covering analysts.
Frequently asked questions
LABP forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month LABP price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $22.93.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.